Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Summary
Eli Lilly is suing six companies that sell illegal versions of its experimental weight-loss drug, retatrutide, which is still in clinical trials and not yet approved by the FDA. The company wants to stop the growing illegal market that sells the drug online and in some stores before it is officially available.Key Facts
- Retatrutide is an experimental weight-loss drug being tested by Eli Lilly and has not yet been approved by the FDA.
- Federal law forbids selling drugs that are not approved, but many companies and clinics are offering retatrutide anyway.
- Eli Lilly has filed lawsuits against six companies, including telehealth firms, peptide sellers, a med spa, and a pharmacy.
- Some of these companies sell retatrutide labeled "for research use" without requiring a prescription.
- The illegal drug supply is believed to come from overseas manufacturers.
- Eli Lilly plans to seek official FDA approval for retatrutide in early 2027.
- Analysts expect retatrutide to be a very successful drug once approved, but worry about the impact of the illegal market.
- Illegal sales have been found in places like convenience stores, often openly advertised without apparent punishment.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
